Any current/future new fundraising through debt or equity?

The transcript of Hester Biosciences Limited's Q2/H1 FY25 earnings call held on 28 October 2024 does not mention any current or planned fundraising through debt or equity. The management, including CEO Rajiv Gandhi and Executive Director Priya Gandhi, focused on business growth, product launches, operational efficiency, and expansion of divisions (Animal Healthcare, Poultry Healthcare, Pet Care). No statements were made regarding new debt issuance or equity fundraising initiatives. Subsidiaries like Hester Nepal have become debt-free, indicating a focus on improving cash flow and financial hea

Any current/future capex/capital investment/strategic investment?

The transcript does not specifically mention any current or planned capital expenditure (capex) or strategic investments. The management emphasizes focus on strengthening the Animal Healthcare division and improving company cash flow. They aim to expand product portfolios, particularly in Pet Care, with plans to launch at least one pet vaccine within a year. Continued investment in R&D is highlighted through pipelines of vaccines and acquisition of technologies from government institutes. The company intends to introduce new products to diversify offerings and drive growth. Overall, the strate

Future growth expectations in sales/revenue/volumes?

Company is on an upward trajectory in both top line and bottom line. Animal Healthcare division grew 20% in H1 FY25; growth driven by sustained demand in dairy sector. Poultry Healthcare division showed strong 27% growth in H1 FY25, supported by 59% increase in poultry vaccine exports. Pet Care division achieved 20% growth in H1 FY25; viewed as a promising future growth driver. Focus on strengthening Animal Healthcare and expanding Pet Care, including launching at least one pet vaccine within a year. New product launches, such as Diet Fortify (prescription-based pet food), are contributing to

Future growth expectations in earnings/operating earnings/profits/EPS?

Hester Biosciences is on an upward trajectory in both top line (revenue) and bottom line (profit), with significant PAT increase of 38% and operational efficiency gains reflected in improved margins. Focus remains strongly on bottom line improvement with sustained growth expected across divisions. Animal Healthcare division grew 20% in H1 FY25; continued growth anticipated driven by dairy sector demand and government tenders. Poultry Healthcare division posted 27% growth in H1 FY25 with ongoing efforts to maintain this momentum, supported by vaccine sales and health products. Pet Care division

Current/ Expected Orderbook/ Pending Orders?

There is no specific mention of the current or expected order book or pending orders in the transcript. However, the management highlighted continued growth and positive trends across divisions. Export orders and domestic vaccine needs were fulfilled by Hester Nepal, improving cash flow. Focus remains on capitalizing on trade demand and government tender requirements, especially for Goat Pox and PPR vaccines. The company is optimistic about sustained demand in the dairy sector and increasing global demand for poultry products. They aim to introduce new products and improve operational efficien

Hester BiosQ2 FY25Pharmaceuticals & Biotechnology

Hester Bios Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,127P/E: 35.0Market Cap: ₹1.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Company is on an upward trajectory in both top line and bottom line.
Animal Healthcare division grew 20% in H1 FY25; growth driven by sustained demand in dairy sector.
Poultry Healthcare division showed strong 27% growth in H1 FY25, supported by 59% increase in poultry vaccine exports.
Pet Care division achieved 20% growth in H1 FY25; viewed as a promising future growth driver.
Focus on strengthening Animal Healthcare and expanding Pet Care, including launching at least one pet vaccine within a year.
New product launches, such as Diet Fortify (prescription-based pet food), are contributing to growth.
Continued efforts to diversify product portfolio and increase operational efficiency.
International subsidiaries (Hester Nepal and Hester Africa) are growing and improving cash flows.
Management remains optimistic about growth prospects across all divisions, banking on both domestic and export markets.

Margin guidance

Category 1

Hester Biosciences is on an upward trajectory in both top line (revenue) and bottom line (profit), with significant PAT increase of 38% and operational efficiency gains reflected in improved margins.
Focus remains strongly on bottom line improvement with sustained growth expected across divisions.
Animal Healthcare division grew 20% in H1 FY25; continued growth anticipated driven by dairy sector demand and government tenders.
Poultry Healthcare division posted 27% growth in H1 FY25 with ongoing efforts to maintain this momentum, supported by vaccine sales and health products.
Pet Care division, identified as a future star, grew 20% in H1 FY25 and aims to launch a pet vaccine within a year, expanding its revenue base.
Improved product mix and operational efficiency will aid margin expansion.
International subsidiaries (Hester Nepal and Hester Africa) show positive trends, contributing to consolidated growth and cash flow improvement.
Overall expectation: sustainable earnings growth, portfolio diversification, and improved cash flow in upcoming quarters.

See what Hester Bios management said on margin guidance — free account, 30 seconds.

Fundraise plans

The transcript of Hester Biosciences Limited's Q2/H1 FY25 earnings call held on 28 October 2024 does not mention any current or planned fundraising through debt or equity.
The management, including CEO Rajiv Gandhi and Executive Director Priya Gandhi, focused on business growth, product launches, operational efficiency, and expansion of divisions (Animal Healthcare, Poultry Healthcare, Pet Care).
No statements were made regarding new debt issuance or equity fundraising initiatives.
Subsidiaries like Hester Nepal have become debt-free, indicating a focus on improving cash flow and financial health rather than raising new debt.
The company’s emphasis is on sustainable growth, new product launches, and operational improvements rather than on raising external capital at this time.

Order book

There is no specific mention of the current or expected order book or pending orders in the transcript.
However, the management highlighted continued growth and positive trends across divisions.
Export orders and domestic vaccine needs were fulfilled by Hester Nepal, improving cash flow.
Focus remains on capitalizing on trade demand and government tender requirements, especially for Goat Pox and PPR vaccines.
The company is optimistic about sustained demand in the dairy sector and increasing global demand for poultry products.
They aim to introduce new products and improve operational efficiency to drive growth.
Overall, while no specific figures on order book or pending orders are provided, the outlook suggests a healthy and growing demand pipeline.

See what Hester Bios management said on order book — free account, 30 seconds.

Capex plans

Yes

The transcript does not specifically mention any current or planned capital expenditure (capex) or strategic investments.
The management emphasizes focus on strengthening the Animal Healthcare division and improving company cash flow.
They aim to expand product portfolios, particularly in Pet Care, with plans to launch at least one pet vaccine within a year.
Continued investment in R&D is highlighted through pipelines of vaccines and acquisition of technologies from government institutes.
The company intends to introduce new products to diversify offerings and drive growth.
Overall, the strategy implies potential future investments in product development and operational expansion but no explicit capex figures or project details are disclosed.

Track Hester Bios — get its next earnings analysis in your feed

How does Hester Bios rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisHester Bios

Rev 3Mar 1

See where Hester Bios sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Hester Bios rank in Pharmaceuticals & Biotechnology?

Compare Hester Bios against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Hester Bios's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →